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Abstract
Objectives: The overall objective of this study was to evaluate and provide evidence
and recommendations on current published literature about diet and lifestyle in the
prevention of type 2 diabetes.
Design: Epidemiological and experimental studies, focusing on nutritional
intervention in the prevention of type 2 diabetes are used to make disease-specific
recommendations. Long-term cohort studies are given the most weight as to strength
of evidence available.
Setting and subjects: Numerous clinical trials and cohort studies in low, middle and
high income countries are evaluated regarding recommendations for dietary
prevention of type 2 diabetes. These include, among others, the Finnish Diabetes
Prevention Study, US Diabetes Prevention Program, Da Qing Study; Pima Indian
Study; Iowa Women’s Health Study; and the study of the US Male Physicians.
Results: There is convincing evidence for a decreased risk of diabetes in adults who are
physically active and maintain a normal body mass index (BMI) throughout
adulthood, and in overweight adults with impaired glucose tolerance who lose weight
voluntarily. An increased risk for developing type 2 diabetes is associated with
overweight and obesity; abdominal obesity; physical inactivity; and maternal diabetes.
It is probable that a high intake of saturated fats and intrauterine growth retardation
also contribute to an increased risk, while non-starch polysaccharides are likely to be
associated with a decreased risk. From existing evidence it is also possible that omega-
3 fatty acids, low glycaemic index foods and exclusive breastfeeding may play a
protective role, and that total fat intake and trans fatty acids may contribute to the risk.
However, insufficient evidence is currently available to provide convincing proof.
Conclusions: Based on the strength of available evidence regarding diet and lifestyle in
the prevention of type 2 diabetes, it is recommended that a normal weight status in the
lower BMI range (BMI 21–23) and regular physical activity be maintained throughout
adulthood; abdominal obesity be prevented; and saturated fat intake be less than 7% of








Type 2 diabetes, formerly known as non-insulin-depen-
dent diabetes (NIDDM), accounts for most cases of
diabetes mellitus worldwide. It is estimated that in 2000
there were approximately 150 million individuals with the
disease and that this number is likely to double by 20251.
Type 2 diabetes is the fourth or fifth leading cause of death
in most developed countries and there is growing
evidence that it has reached epidemic proportions in
many developing and newly industrialised countries2. The
lowest rates of type 2 diabetes are found in rural
communities where people retain traditional lifestyles2.
Dramatic changes in the prevalence or incidence of type
2 diabetes have been observed in communities where
there have been major changes in the type of diet
consumed, from a traditional indigenous diet to a typical
‘Western’ diet, e.g. Pima Indians in Arizona, Micronesians
in Nauru and Aborigines in Australia3–5. Changing disease
rates are almost certainly explained by changes in several
dietary factors as well as by changes in other lifestyle
related factors, notably a reduction in physical activity.
Classification and diagnosis
As undiagnosed diabetes represents an important fraction
of the population with the disease, most epidemiological
studies are undertaken by testing all subjects in the
population of interest. Without systematic testing an
incomplete and potentially misleading picture of the
frequency or distribution of the disease is obtained.
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Furthermore, because of the differences in criteria,
comparisons of rates between recent and earlier studies
should be made with caution.
The 1985 internationally accepted World Health
Organisation (WHO) criteria for the diagnosis and
classification of diabetes led to much greater uniformity
of methods used in epidemiological studies6. Recently, the
diagnostic criteria have been revised, first by the American
Diabetes Association7 and then by the WHO8, thus
complicating comparisons of studies that are analysed
according to the new criteria and those with the earlier
WHO criteria.
The revised diagnostic criteria accord greater import-
ance to the fasting plasma glucose (FPG) concentration as
a criterion for diagnosis. The FPG value considered
diagnostic of diabetes has been lowered to $126 mg/dL
($7.0 mmol/L)7,8 from the former value of 140 mg/dL
(7.8 mmol/L) and over. The category of impaired glucose
tolerance (IGT) was retained at 2-hr post-load glucose
levels from 140 mg/dL (7.8 mmol/L) to less than 200 mg/dL
(11.1 mmol/L). An additional category, impaired fasting
glycaemia (IFG), was introduced to categorise individuals
who have FPG levels that are above normal but fall short
of the new diagnostic FPG level for diabetes, i.e. FPG
110 mg/dL (6.1 mmol/L) to 125 mg/dL (,7.0 mmol/L). It is
now apparent that only a minority of individuals with IGT
have IFG, and conversely, only a minority of those with
IFG have IGT9,10.
The change in diagnostic criteria has resulted in some
individuals being reclassified as having diabetes, i.e.
individuals with FPG from 126 mg to 139 mg/dL and with
post-load 2-hr glucose values of ,200 mg/dL, thereby
resulting in an increase in prevalence9. Furthermore, some
recent papers have reported the prevalence of diabetes
based solely on fasting glucose values, thereby ignoring
individuals with abnormal 2-hr values based on oral
glucose tolerance testing. Such a strategy leads to rates that
are appreciably lower than in studies where glucose
tolerance tests are done.
Epidemiology
Prevalence and incidence of type 2 diabetes
In recent decades, dramatic increases in the prevalence
and incidence of type 2 diabetes have occurred in many
parts of the world especially in the newly industrialised
and developing countries11 (Fig. 1). Indeed, the majority
of cases of type 2 diabetes in the future will occur in
developing countries with India and China having more
cases than any other country in the world1.
In the United States, the most complete information on
the prevalence of type 2 diabetes has been obtained from
the US National Health Examination Surveys12,13. Surveys
carried out in adults aged 20–74 years in representative
samples of the US population show that the prevalence
differs considerably in different ethnic groups13,14 (Fig. 1).
The prevalence in Hispanic Americans, particularly
Mexican Americans, is higher than in the white or black
populations and African Americans have greater preva-
lence than whites15. Native American populations have
prevalence rates of type 2 diabetes which are even higher
than those of Hispanic and African Americans, although
the prevalence does vary from one native American group
to another16,17.
Data from the health examination surveys (NHANES
III) conducted between 1988 and 1994 showed that 5.1%
of US adults aged 20 years and older had previously
diagnosed diabetes12. The prevalence of undiagnosed
diabetes, based only on FPG levels of $126 mg/dL, was
2.7%, whereas with glucose tolerance tests and using the
1985 WHO criteria was 6.3%9. The total prevalence was
7.8% based on diagnosed diabetes and FPG levels only,
or 11.4% when based on the 1985 WHO criteria, rates
appreciably higher than seen in earlier surveys.
Among persons aged 40–74 years the prevalence
(based on the fasting criteria) had increased from 8.9%
in 1976–1980 to 12.3% in 1980–1994—a 38% increase
over the course of a decade12. Data from the
Behavioural Risk Factor Surveys, carried out on
representative samples of US adults, 18 years and
older, indicated an increase of diagnosed diabetes
between 1991 and 1999 from 4.1 to 6.0% in men, and
from 5.6 to 7.6% in women, an increase of approxi-
mately 40% in less than a decade18,19.
Turning to the situation in developing populations, in
African Sub-Saharan countries, formerly, the disease either
was absent, or was very low in occurrence. Even as late as
1987, in a rural village in Togo, West Africa, none of a large
series of subjects examined had diabetes20. In South
Africa, formerly, the disease was rare in rural areas21,
moreover, even in urban centres the proportion affected
was low, 1.1%22. However, in strong contrast, in present
day city populations, as in Durban in 1993, the crude
incidence rate in Africans is actually higher than that in the
local white population, namely 6.7 versus 4.5%23.
Fig. 1 Prevalence of diabetes according to 1980 WHO criteria in
men and women aged 30–64 years in different countries and
various ethnic groups (adapted from King and Rewers11)
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Increases in type 2 diabetes have been observed in
many other populations in the past half-century. For
example, among the Pima Indians a 40% increase in the
prevalence occurred between 1967 and 1977, primarily
due to an increase in the incidence (the rate of
development in new cases) of the disease17.
Incidence studies using standardised glucose tolerance
tests have been performed in the Pima Indians of
Arizona24,25 and among Micronesians in the central Pacific
island of Nauru26, populations with very high incidence
rates. Among Pima Indians, the age-specific incidence and
aged-adjusted incidence rates of diabetes have increased
over the course of two decades25,27 whereas in Nauru, the
incidence may now be falling.
Mortality
Type 2 diabetes is associated with excess mortality mainly
attributable to the vascular complications of the disease. In
Caucasian populations, much of the excess is attributable
to cardiovascular disease, especially ischaemic heart
disease28–30, but in others such as Asian and American
Indian populations renal disease contributes to a
considerable extent31,32. In some developing nations, an
important component of the excess is due to infections33.
Age-adjusted mortality rates among persons with
diabetes are 1.5–2.5 times higher than in the general
population28,30 but the excess is greater in younger age
groups and diminishes at older ages. The excess mortality
leads to a decreased life expectancy among those with
type 2 diabetes32,34. The extent of the reduction of life
expectancy is dependent on the age of onset of the
disease, but averages approximately 10 years in countries
such as the United States. Mortality in women is generally
lower than in men, but the relative risk of death in women
with diabetes is increased so that the absolute rates
approach those seen in men with type 2 diabetes35,36.
Increased mortality in patients with type 2 diabetes is
seen mainly among those with complications. Risk factors
include proteinuria and retinal disease, and the classical
risk factors for heart disease. Hyperlipidaemia, hyperten-
sion and smoking each contribute disproportionately to
death rates among those with type 2 diabetes37. Mortality
rates also increase with increasing duration of the
disease30,32.
Metabolic changes during development of type 2
diabetes: insulin resistance and impaired glucose
homeostasis
Resistance to the action of insulin is the underlying
abnormality in most people who develop type 2
diabetes38,39 (Fig. 2). Insulin resistance results from an
interaction between genetic and environmental factors.
The genetic factors are not clearly understood and it is also
uncertain whether some environmental factors are more
important than others. A wide range of lifestyle related
factors has been implicated, ranging from early life events
to physical inactivity, several dietary attributes and
subsequent development of overweight and obesity.
These factors may be associated both with the develop-
ment of insulin resistance as well as with progression from
insulin resistance to states of impaired glucose metabolism
(IFG, IGT) and eventually type 2 diabetes. The initial
reaction of the b cells is to increase output of insulin in
order to overcome the insulin resistance and so to
maintain normal blood glucose levels.
Fasting insulin concentrations in subjects with normal
glucose tolerance represent a surrogate marker of insulin
resistance and numerous longitudinal studies have shown
that higher fasting insulin levels (or other indices of insulin
resistance) predict the development of type 2 diabetes.
Unless insulin resistance is reversed, hypersecretion of
insulin is usually insufficient to maintain normoglycaemia
indefinitely and progression to IGT and IFG follows39–42.
These early abnormalities of glucose metabolism usually,
progress further to type 2 diabetes43,44. While raised levels
of insulin are invariably associated with insulin resistance,
the insulin secretion declines at a variable rate as the
disease progresses through IGT to type 2 diabetes. This
occurs either because of an inherent defect of the b cell or
because of glucotoxicity, whereby the b cell is damaged as
blood glucose levels rise45. The extent to which this
sequence of events can be halted or reversed is considered
in Section 8.
IGT or type 2 diabetes often coexist with other clinical
and metabolic abnormalities which are associated with
insulin resistance and central obesity. Hypertension,
raised levels of triglyceride, reduced levels of high density
lipoprotein, hyperuricaemia and raised levels of plasmi-
nogen activator inhibitor-1 are some of the constellation
of features which along with hyperglycaemia of varying
severity constitute the ‘syndrome’ now known as the
metabolic syndrome or insulin resistance syndrome46–50.
These features all contribute to the increased risk of
cardiovascular disease associated with IGT and type 2
diabetes and may coexist together with hyperinsulinaemia
before abnormalities of blood glucose are detectable.
Fig. 2 Stages and risk factors in the development of type 2
diabetes
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Irreversible risk factors
The following section deals with important risk factors for
the development of type 2 diabetes, which are based on
inherent genetic or developmental factors, which are not
modifiable by dietary and/or other lifestyle changes.
Race/ethnicity
The prevalence of type 2 varies considerably among
populations of different ethnic origins living in apparently
similar environments11. For example, in Singapore the
frequency of diabetes in 1992 was 8.5–7.7% in Chinese
men and women aged 18–69 compared with 13.3 and
12.3%, respectively, among the Asian Indians and
Malays51. High prevalence rates of diabetes have also
been found among Asian Indians compared with the
indigenous populations in the United Kingdom, Fiji, South
Africa and in the Caribbean52–54. Considerable differences
in the prevalence of diabetes have also been described
among the multi-ethnic populations of Hawaii and New
Zealand, where the Native Hawaiians and Maori
populations, both of Polynesian origin, have higher
prevalences than other ethnic groups55,56. While environ-
mental factors undoubtedly account for some of these
differences, they are likely also to reflect inherent ethnic
differences in susceptibility to the disease.
Familial aggregation
The empirical risk of having type 2 diabetes is increased
2 to 6-fold if a parent or sibling has the disease57.
Consequently, a positive family history is a practical, albeit
a crude way, of estimating if an individual is likely to have
inherited susceptibility to the disease. On the other hand,
familial aggregation may occur for non-genetic reasons.
Family members often share a similar environment,
particularly as children and in adolescence, thus familial
aggregation alone is not definitive evidence of genetic
determinants. Furthermore, with a disease as frequent as
type 2 diabetes two or more family members may well
have the disease by chance alone.
Genetic factors
A higher degree of concordance for type 2 diabetes in
identical twins than in dizygotic twins provides strong
evidence that genetic factors are important in determining
susceptibility58,59. However, the fact that not all mono-
zygotic twins are concordant for the disease confirms the
importance of environmental factors.
Further evidence of the importance of genetic factors as
predisposing factors for type 2 diabetes comes from
studies of admixed populations. Differences in prevalence
among persons of mixed racial background from that in
parent populations with notably different prevalence of
the disease are indicative of the importance of genetic
determinants. Such relationships have been described
among Nauruans and Pima Indians where full-heritage
members of these groups have significantly higher rates of
diabetes than those of mixed heritage60,61. Similarly,
among the Mexican American population of San Antonio,
the prevalence of type 2 diabetes is related to the degree of
American Indian admixture, with higher rates associated
with greater proportions of American Indian genes62.
Much research activity has centred on attempts to
unravel the genes, which confer susceptibility to type 2
diabetes, a number of genes are likely to be involved.
At present, it is impossible to quantify the
relative contributions of genetic and environmental
factors.
Age and gender
The prevalence and incidence of type 2 diabetes vary to
some extent between the sexes from one population to
another, but these differences are relatively small and
appear to be accounted for by differences in other risk
factors such as obesity and physical activity.
The prevalence of type 2 diabetes increases with age
although the patterns of incidence vary considerably. In
high incidence populations, the prevalence may increase
markedly in the younger adult years (e.g. 20–35 years of
age), whereas in others the incidence and prevalence
increase mainly in older individuals (e.g. 55–74 years of
age). In most populations, a decrease in prevalence is seen
in the oldest age groups (e.g. 75þ years) because of higher
mortality rates in those with the disease.
Type 2 diabetes in relatively affluent societies usually
develops in the middle to older age groups. In developing
countries, however, because of the younger age distri-
bution of the population, many cases occur in young and
middle aged adults. In Caucasian populations in the
United States and Europe, the prevalence of type 2
diabetes increases with age at least into the seventies63.
Type 2 diabetes was formerly considered as a disease of
adults. In recent years, however, there have been
many reports of its occurrence in childhood and
adolescence64–66. As in adults, the disease in children is
frequently asymptomatic and is detected mainly by
screening. In Japan, a national programme for screening
school children has been in place since 1992 and the
numbers recognised to have type 2 diabetes have
increased progressively so that the prevalence and
incidence of type 2 diabetes greatly exceed those of type
1 diabetes67. In American Indian children and adolescents,
type 2 diabetes was first described among the Pima
Indians68 and the prevalence has increased steadily over
the past 30 years64. Reports of type 2 diabetes in this age
group have appeared from many ethnic groups in
recent years including other Native American tribes,
Mexican Americans, African Americans, Chinese,
Polynesians, Asian Indians and Arabs from the Gulf States.
It appears that among Caucasians, type 2 diabetes is
still seen relatively infrequently in children and young
adults.
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Modifiable risk factors
This section comprises a review on risk factors related to
dietary and other lifestyle factors. These factors have been
shown to have an increased or a decreased risk for the
development of type 2 diabetes and can be modified by
lifestyle changes.
Obesity
Obesity is a frequent concomitant of type 2 diabetes, and
in many longitudinal studies has been shown to be a
powerful predictor of its development25,69. Obesity has
increased rapidly in many populations in recent years70–72
because of an interaction between genetic and
environmental factors. These include: metabolic charac-
teristics73–75; physical inactivity74,76–78; habitual energy
intake in relation to expenditure76; and macronutrient
composition of the diet78–84.
This increase in obesity has been accompanied by an
increasing prevalence of type 2 diabetes19. Since obesity is
such a strong predictor of diabetes incidence, it appears
that the rapid increases in the prevalence of type 2
diabetes seen in many populations in recent decades are
almost certainly related to increasing obesity. Data from
the Nurses’ Health Study suggest that the lowest risk of
diabetes occurs in individuals who have a body mass
index (BMI) ,21, with increasing prevalence seen as
obesity levels increase69.
Only a limited number of studies have measured age
and sex specific incidence rates for type 2 diabetes in
relation to obesity. Such rates vary considerably according
to other risk factors. There are large differences in age-
specific incidence rates according to BMI in the Pima
Indians25. Those with higher BMI have much higher
incidence rates of type 2 diabetes at earlier ages than those
with lower BMI among whom the incidence rises in the
older age groups. In non-obese individuals, the incidence
of type 2 diabetes is low even in populations such as the
Pima Indians where the overall risk of the disease is very
high. The relationship of incidence of type 2 diabetes to
obesity also varies with other risk factors. For example, in
the Pima Indians the incidence rises much more steeply
with BMI in those whose parents have diabetes than in
these who do not. This relationship indicates an
interaction between risk factors.
Several studies indicate that waist circumference or
waist-to-hip ratio may be a better indicator of the risk of
developing diabetes than BMI85–87. Such data suggest that
the distribution of body fat is an important determinant of
risk as these measures reflect abdominal or visceral obesity.
In Japanese American men, for example, the intra-abdom-
inal fat, as measured from CAT scans, was the best
anthropometric predictor of diabetes incidence86.
Given the importance of central adiposity as a
determinant of diabetes risk it is necessary to consider
whether the usually quoted ‘normal range’ for BMI
(18.5–24.9 kg/m2) is appropriate for all populations. It
might be appropriate to also suggest an appropriate range
for some measure of the distribution of body fat (e.g. waist
circumference, waist/hip ratio). The Nurses Health Study
suggests that for populations of European descent risk of
type 2 diabetes increases even within the normal BMI
range and that a BMI of 21 kg/m2 might be an optimum
level69. However, for a given BMI, several (perhaps all)
populations of Asian descent appear to have an
appreciably greater proportion of body fat than that of
Europeans. It seems conceivable, therefore, that a lower
BMI might be desirable88. In the absence of definitive data
from prospective studies in these countries, at present it
may be appropriate to similarly suggest an optimum level
towards the lower end of the normal range. On the other
hand, people of Pacific descent (Polynesians) have a
relatively high proportion of lean body mass compared
with Europeans for any given BMI. Therefore, a higher BMI
cut off may be acceptable. However, the particularly high
risk of type 2 diabetes and other co-morbidities of obesity
in these populations may negate this apparently beneficial
anthropometric attribute. Again, in the absence of
appropriate prospective studies, it may be wise to suggest
that their BMI should not exceed the conventional normal
range. Because there are fewer data available concerning
waist circumference or waist/hip ratio in different
populations, it is appropriate to continue to use the
WHO recommended BMI range (18.5–24.9 kg/m2) and
population mean of 21 kg/m2 88.
Physical inactivity
Numerous studies have indicated the importance of
physical inactivity in the development of type 2
diabetes89 – 92. Indeed, in most studies its relative
importance may be underestimated because of impreci-
sion in measurement. In the Nurses’ Health Study, women
who reported exercising vigorously had an age-adjusted
incidence rate of self-reported clinically diagnosed
diabetes that was two-thirds as high as that of women
who exercised less frequently89. The deleterious effect of
low levels of physical activity is seen particularly among
those subjects who have other risk factors such as high
BMI, hypertension or parental diabetes. Similarly, among
male physicians, the incidence of self reported diabetes
was negatively related to the frequency of vigorous
exercise and the strength of this relationship was greater in
those with higher BMI90. For equivalent degrees of
obesity, more physically active subjects have a lower
incidence of the disease92.
Recommendations with regard to physical activity as a
preventative measure for developing type 2 diabetes are
still difficult to quantify. Currently, guidelines propose
moderate physical activity on at least 5 days per week and
do not specify heart rate targets However, more recent
evidence suggests that vigorous exercise is required to
improve insulin sensitivity93. A study by McAuley et al.93
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showed that insulin sensitivity improved in normoglycae-
mic insulin-resistant adults who undertook vigorous
exercise and not in those who complied with current
moderate exercise programmes. The vigorous exercise
programme required participants to train five times a week
for at least 20 min per session at an intensity of 80–90% of
age-predicted maximum heart rate93.
Fat: quantity and quality
Both the amount and quality of dietary fat may modify
glucose tolerance and insulin sensitivity94–96. A high fat
content in the diet may result in deterioration of glucose
tolerance by several mechanisms including decreased
binding of insulin to its receptors, impaired glucose
transport, reduced proportion of glycogen synthase
and accumulation of stored triglycerides in skeletal
muscle97–101. The fatty acid composition of the diet, in
turn, affects tissue phospholipid composition, which may
relate to insulin action by altering membrane fluidity and
insulin signalling94.
Amount of fat consumed
In experimental animals, all high-fat diets (with the
exception of n-3 fatty acids) have been shown to result in
insulin resistance relative to high carbohydrate diets
94,99,100,102,103. The data from epidemiological and human
intervention studies are less consistent. In two cross-
sectional studies, total fat intake was higher in glucose
intolerant and type 2 diabetic subjects104 and in subjects
with recurrent gestational diabetes mellitus105 compared
with normoglycaemic controls. Furthermore, a high fat
intake has been shown to predict development of IGT in a
group of healthy subjects106 and progression from IGT to
type 2 diabetes in a group of subjects with IGT107. High
total fat intake has also been associated with higher fasting
insulin concentrations108,109 and a lower insulin sensitivity
index110. On the other hand, there are several studies,
which show no association between diabetes risk and total
fat intake111–119. Few human intervention studies have
examined the effects of high fat, low carbohydrate diets on
diabetes risk, and the results have been inconsistent120–127.
Nature of dietary fat
As previously mentioned, in animal experiments saturated,
monounsaturated and polyunsaturated fats, excluding n-3
fatty acids, have caused insulin resistance when fed as
high-fat diets94,99,100,102,103. In epidemiological studies, a
high saturated fat intake has been associated with higher
risk of IGT106,128 and higher fasting glucose129,130 and
insulin levels108,131. Higher proportions of saturated fatty
acids in serum lipids/muscle phospholipids have been
associated with higher fasting insulin levels132, lower
insulin sensitivity133 and higher risk of developing type 2
diabetes134. Higher vegetable fat (unsaturated fat) and
PUFA intake have in turn been associated with a lower risk
of type 2 diabetes115,118,119, as well as lower fasting and
2-hr glucose concentrations130,135. Furthermore, higher
proportions of long-chain polyunsaturated fatty acids in
skeletal muscle phospholipids have been associated with
better insulin sensitivity in humans136,137. With respect to
monounsaturated fatty acids, the epidemiological data are
inconsistent. Some studies indicate that a high intake of
monounsaturated fatty acids may be detrimental in terms
of increasing diabetes risk106,138. However, it should be
noted that in a typical ‘Western’ diet the monounsaturated
fatty acids are not derived from vegetable oils but to a large
extent coexist with saturated fat in sources such as meat
and milk products. Therefore, the detrimental effects
reported106,138 may be due to the effects of saturated fatty
acids in these food sources106.
In two short-term human intervention studies, replace-
ment of a considerable portion of saturated fat by
unsaturated fat improved glucose tolerance in young
healthy women139 and in middle-aged glucose-intolerant
hyperlipidaemic subjects140. A longer-term study by
Vessby et al.141 confirmed that a substitution of mono-
unsaturated fat for saturated fat significantly improved
insulin sensitivity in healthy subjects after a 3-month
dietary period. An interesting interaction between total fat
intake and fatty acid composition of dietary fat was
reported: the favourable effect of substituting monounsa-
turated fat for saturated fat was lost in individuals
consuming more than 37% of energy as fat141. There are
only a few studies in which the effects of single fatty acids
on glucose and insulin metabolism have been examined.
In two short-term studies with single saturated fatty
acids—lauric, palmitic and stearic acids—no effect on
glucose and insulin metabolism was found when these
saturated fatty acids were compared with an equivalent
energy exchange with monoenes142,143.
In the light of present knowledge regarding the
relationships between type 2 diabetes and nature and
quantity of dietary fat, as well as the absence of definitive
data regarding precise percentage of fat to total energy, it
seems reasonable to suggest that quantitative recommen-
dations should follow those suggested for reduction of
cardiovascular risk.
The role of trans fatty acids
Data on the effects of trans fatty acids on glucose
metabolism are sparse. A report from the Nurses Health
Study118 suggests a positive association between trans fatty
acid intake and risk of type 2 diabetes. In mouse islet cells
trans fatty acids potentiate insulin secretion compared
with cis-isomers144. Two human experiments have been
reported. In patients with type 2 diabetes, a 6-week diet
high in trans fatty acids (20% of energy) increased post-
prandial c-peptide and insulin responses compared with a
diet high in cis-monounsaturated fatty acids145. In healthy
young women, consumption of a 4-week diet with 5% of
energy from trans fatty acids did not change insulin
sensitivity compared to an oleic acid enriched diet146.
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The role of n-3 fatty acids
In rodent studies, n-3 fatty acids ameliorate insulin
resistance induced by high-fat feeding 95,100,103. In some
epidemiological studies, an inverse association between
fish intake and risk of IGT has been observed106,114. Most
intervention studies aimed at investigating the effect of fish
oil on insulin sensitivity have been done in patients with
type 2 diabetes and have been negative147–151. A negative
result has, however, also been reported in healthy
subjects141.
Carbohydrates: quantity and quality
Total carbohydrates
As mentioned earlier, some controversy surrounds the
optimal ratio of carbohydrate-to-fat in the diet with respect
to the prevention of chronic diseases, including type 2
diabetes. The main question is whether high intakes of
either carbohydrate or fat are deleterious over time and
will predispose individuals to diabetes152.
Due to a paucity of controlled trials on which to base
recommendations for macronutrients we have to rely on
the available evidence from epidemiological studies.
Causal inferences thus need to be made with the
recognition that the probability of confounding variables
may exist in the different populations73. There are marked
differences in various countries of the world with respect
to the fat-to-carbohydrate ratios consumed by different
populations153. A significant positive association has been
shown between dietary fat consumption and the
proportion of the population who are overweight. This
supports the notion of a reduced fat (increased carbo-
hydrate) intake as a preventative measure for chronic
diseases154. There is some evidence that a high carbo-
hydrate intake decreases the prevalence of diabetes104,155.
However, numerous studies have reported that an
increased intake of carbohydrates can reduce HDL levels
and raise fasting plasma triacylglycerol concentrations156–
160. These are mainly short-term, isocalortic, metabolic
studies rather than long-term ad lib studies where weight is
allowed to decrease on the lower fat content diets.
Two cohort studies116,117–161 and a recent review162 did
not find an association between total carbohydrate and
diabetes risk. It is known that a high carbohydrate intake
increases the requirement for insulin secretion in order to
maintain glucose homeostasis163. Insulin secretion by
beta-cells is glucose sensitive and a high intake of
carbohydrate in relation to energy intake, produces higher
post-prandial insulin levels. It is possible that repeated
stimulation of a high insulin output by a high carbohydrate
diet could speed up an age-related decline in insulin
secretion and lead to an earlier onset of type 2
diabetes152,164. The quality as well as the quantity of
carbohydrate may hasten this response152. The most
recent American dietary guidelines recommend intake of a
variety of grain products (including whole grains)
equating to six or more servings a day165. The FAO/WHO
recommend that carbohydrate in the diet should comprise
at least 55% of total energy intake in ‘normal’ healthy
individuals166. There is, however, no specific carbohydrate
guideline, which is aimed at the prevention of type 2
diabetes. Therefore, a wide range of carbohydrate intakes
may be acceptable in terms of achieving a low risk of type
2 diabetes with type and source of carbohydrate being
more important than quantity.
Dietary fibre and the glycaemic index
Dietary fibre in this context is composed of non-starch
polysaccharides (NSPs), plus lignin, oligosaccharides and
resistant starch. Resistant starch is that portion of starch
that resists digestion, passes into the lower intestine, and
ferments there. Dietary fibre found in foods consists of
cellulose, hemicelluloses, pectins, hydrocolloids, resistant
starches and resistant oligosaccharides166. Dietary fibre is
one of the factors that influences post-prandial glucose
and insulin responses. Other factors include the macro-
nutrient composition of meals, processing, cooking and
other characteristics of the carbohydrates167–170. Since
there are considerable differences in the physiological
responses to different forms of carbohydrate, the term
glycaemic index (GI) was coined in 1981171. It is defined as
the glycaemic response elicited by a 50 g carbohydrate
portion of a food expressed as a percentage of that elicited
by a 50 g portion of a reference food (glucose or white
bread). GI is a measure of the post-prandial glucose
response after carbohydrate consumption. Low GI foods
have lower 2-hr areas under the glucose curve than the
reference food, while high GI foods have higher areas.
The effects of the various components of dietary fibre
have been implicated in the prevention and management
of a range of diseases, including type 2 diabetes, as early as
the seventies172,173. Cross-sectional studies suggest that
lack of dietary fibre may be a causative factor in type 2
diabetes and have shown an inverse relationship between
fibre intake and blood insulin levels110,174; implying that
fibre improves insulin sensitivity. Three large cohort
studies, the Health Professionals Follow-up study carried
out on men aged 40–75117, the Nurses Study carried out
on women aged 40–65116, and the Iowa Women’s Health
Study carried out on women aged 55–69 years161 have
studied the effects of fibre and glycaemic load on risk of
developing diabetes. All three studies clearly showed that
a relatively low intake of dietary fibre significantly
increased the risk of type 2 diabetes. The association
was found to be strong for cereal fibre, a rich source of
insoluble fibre, but much weaker for sources of soluble
fibre117– 161,175,176. The protective association in the
extreme quintiles revealed a risk ratio of 0.64–0.72, after
correcting for related variables such as age, BMI, smoking
and physical activity. Two of the studies reported that
glycaemic load is associated with risk of diabetes116,117.
They showed an increased relative the risk of type 2
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diabetes of 2.2 in women and 2.1 in men, with a
combination of low cereal fibre intake and a high
glycaemic load. However, the third cohort study did not
detect a risk associated with GI117. Studies carried out in
people with diabetes shed further light on the possible
roles of dietary fibre and GI. Many studies have shown that
glycaemic control is improved and the total LDL
cholesterol reduced on relatively high carbohydrate, low
fat diets including naturally occurring fibre-rich foods
compared with relatively low carbohydrate, higher fat
diets. A similar benefit has also been shown when
comparing diets with similar carbohydrate:fat ratios, but
with the experimental diet being appreciably higher in
fibre. Feeding supplements of dietary fibre for several
weeks has also been shown to lower both post-prandial
glycaemia, insulin levels177–179 and an overall improve-
ment in glycaemic control as measured by HbA1. This is
seen both in normal subjects and in those with type 2
diabetes. Of considerable interest is the fact that in the
dietary intervention studies, soluble forms of dietary fibre,
regardless of whether it was taken as a supplement or in
food, had an appreciably greater beneficial effect than was
the case for insoluble, largely cereal derived forms of
dietary fibre. Numerous studies have illustrated beneficial
effects of a diet comprising foods with a low GI in type 2
diabetics180–183. Furthermore, some studies have found
that foods with a high GI increase fasting triacylglycerol
concentrations, even when the amount of carbohydrate is
kept constant184,185.
Recently, investigators have also considered the
possibility that factors other than fibre that are contained
in cereals and legumes may influence the risk for chronic
diseases186. Some of these include micronutrients such as
selenium and vitamin E, antioxidants, phytochemicals,
isoflavins and lignans. Since many of these factors occur
together in cereals it is difficult to determine the precise
benefits of each. While the benefits of the ‘whole’ grains
have been demonstrated to reduce risk of CHD in women
in the Nurses Health Study187 and in the Iowa Women’s
Health Study188, the effects of whole grains on the
reduction of type 2 diabetes risk remains to be explored.
In general dietary recommendations, the recommended
fibre intake in terms of NSPs has been set at an average
intake of 18 g (range 12–24 g) of NSP per day for adults in
the UK189 and at 25 g fibre in the USA165. Good sources of
NSPs (.4 g per portion) are: legumes, pulses, brussels
sprouts, whole wheat bread, rye bread, wholemeal pasta,
bran cereals and wholegrain cereals190. However, the wide
range of studies quoted here suggest that an appreciably
larger quantity is required to reduce the risk of diabetes or
improve glycaemic control in those with the disease. Since
there is no clear indication regarding the precise quantity
of dietary fibre to protect against diabetes, or which type
of dietary fibre confers the greatest benefit, it may be most
appropriate to emphasise appropriate carbohydrate
sources rather than to specify precise quantities.
Micronutrients
Vitamin E
Studies in patients with type 1 diabetes have revealed an
increased level of oxidative stress191 and evidence that
vitamin E may help prevent this192. However, little is
known concerning the relationship between vitamin E
intake and the development of type 2 diabetes.
Two cohort studies conducted in Finland examined the
relationship between the blood level of vitamin E and the
risk of type 2 diabetes193,194. One study reported that a low
plasma level of this anti-oxidant vitamin is associated with
a 3.9-fold elevated risk of developing the disease193. The
association was independent of various possible con-
founding factors. A nested case–control study carried out
within a cohort study reported that subjects with a high
serum vitamin E level had a 39% lower risk of diabetes
compared to those with a low level of vitamin E194.
However, in contrast to the previous study193 this
association disappeared when the risk ratio was adjusted
for various coronary heart disease risk factors. This
suggests that a high level of vitamin E may be merely a
marker for a healthy lifestyle.
While the relationship between vitamin E and the risk of
diabetes should be further investigated, there is insuffi-
cient evidence that an increased intake of this nutrient will
prevent the disease.
Magnesium
Three large American cohort studies have reported a
strong negative association between intake of magnesium
and risk of type 2 diabetes. This was seen in the Health
Professionals Follow-up Study carried out on men aged
40–75117, the Nurses Study carried out on women aged
40–65116, and the Iowa Women’s Health Study carried out
on women aged 55–69161. In each case the protective
association in the extreme quintiles revealed a risk ratio of
about 0.7, after correcting for related variables such as age,
BMI, smoking and physical activity. While the association
was attenuated after adjusting for cereal fibre, an
important source of magnesium, the protective association
remained strong and statistically significant. In contrast to
these reports, no association was seen between mag-
nesium intake and risk of type 2 diabetes in the ARIC
study, a cohort study on men and women aged 45–64195.
However, this study was considerably smaller than the
other three and, therefore, had much less statistical power.
In the absence of any evidence regarding mechanisms of
action, it seems inappropriate to offer recommendations
regarding intake.
Chromium
The relationship between chromium and glucose
metabolism has been under investigation since the late
1950s196–198. Anderson et al.199 reported that subjects
with mildly impaired IGT showed an improvement in
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glucose tolerance and a lower level of blood insulin after
receiving chromium supplementation. This was not seen
in subjects with normal glucose tolerance. The subjects
had been consuming a low intake of chromium. This
study suggests that when the intake of chromium is low,
some people develop glucose intolerance, which can be
corrected by chromium supplementation. The lowering
in blood insulin level indicates that the chromium
improves tissue sensitivity to insulin (i.e. helped reverse
insulin insensitivity). Comparable observations have
been reported from studies in rats200–202. A study
undertaken with adults who already have type 2
diabetes showed improved glycaemic control with
chromium supplements, compared with placebo203.
Alcohol intake
Several studies have suggested that moderate alcohol
intake is associated with a reduced incidence of type 2
diabetes. Among women in the Nurses Health Study, there
was a reduced incidence of diabetes in women who
consumed alcohol compared with those who did not.
There was a strong inverse relation between alcohol
consumption and body weight, which could explain much
of the apparent protective effect of alcohol consump-
tion204. Among 20,000 male physicians, those consuming
more than 2–4 drinks per week had a lower incidence of
type 2 diabetes in the subsequent 12 years compared with
non-drinkers, relationships that persisted after adjustment
of BMI and other diabetes risk factors205,206.
These apparent male–female differences were exam-
ined among 12,000 45–64 year old participants in the
Atherosclerosis Risk in Communities Study (ARIC)207.
After adjustment for other diabetes risk factors men
consuming more than 21 drinks per week had a significant
increase in the incidence of diabetes, whereas no
significant association with alcohol intake was found
among the women. The apparent inconsistencies in the
results of these studies preclude clear recommendations
regarding alcohol in the prevention of diabetes.
Intrauterine environment
There has been much recent interest in the extent to which
intrauterine environment may influence the subsequent
risk of developing diabetes and other diseases. Gestational
diabetes, which is a strong risk factor for development of
type 2 diabetes, is also considered here because of its
association with overweight in pregnancy and possible
intrauterine factors, which may play a role in the offspring.
Gestational diabetes
Gestational diabetes (diabetes first recognised during
pregnancy) is more frequent among women from
subgroups of the population who have a high risk of
type 2 diabetes, e.g. older, overweight or obese women,
certain ethnic groups. In some cases, gestational diabetes
represents diabetes that was present, but undiagnosed
before pregnancy, whereas in others it develops during
pregnancy, most frequently towards the end of the second
trimester. It is in this latter group, that following delivery
glucose tolerance is likely to become normal, but such
women carry a high risk for developing diabetes
subsequently208,209.
The intrauterine environment influences the risk of
developing type 2 diabetes. Offspring of diabetic
pregnancies are often large and heavy at birth; they tend
to develop obesity in childhood and are at high risk of
developing type 2 diabetes at an early age210. Such
individuals have lower insulin secretion than similarly
aged offspring of non-diabetic pregnancies211.
A substantial part of the excess risk of diabetes in the
offspring of diabetic pregnancies appears to be the result
of exposure to the diabetic intrauterine environment.
Among offspring born to mothers before and after the
development of type 2 diabetes, those born after the
mother developed diabetes, have a 3-fold higher risk of
developing diabetes than those born before212. Thus, the
enhanced risk among the offspring from diabetic
pregnancies among such women appears to be the result
of intrauterine programming that has long-term effects on
the offspring in later life. The early appearance of type 2
diabetes in female offspring increases the likelihood that
their offspring in turn will be exposed to a diabetic
intrauterine environment, leading to an increased preva-
lence of diabetes in subsequent generations.
Intrauterine growth retardation and low birth
weight
Evidence that type 2 diabetes may be programmed during
foetal development comes from numerous studies on
adults213–221. These showed an association between birth
weight and abnormal glucose–insulin metabolism in later
life. The prevalence of type 2 diabetes and IGT in adults
was found to decrease from 40% by those who weighed
,2.54 kg to 14% among those who weighed .4.31 kg at
birth213. In Pima Indians, this relationship was found to be
U-shaped, with a high prevalence of diabetes also found in
those who had a birth weight.4.5 kg216. Additionally, the
highest prevalence of type 2 diabetes was found in people
who were small at birth and obese as adults213,218. Low
birth weight is also associated with other traits that are
associated with the development of diabetes including
increased blood pressure, elevated triglycerides and lower
HDL concentrations—all characteristic of the insulin
resistance or metabolic syndrome222.
Studies in many populations indicate that low-birth
weight babies have an increased risk of developing type 2
diabetes in adult life213,223–226. This relationship was first
described by Hales and Barker227 who suggested that low
birth weight due to nutritional deprivation in utero
resulted in reduced beta-cell mass. They suggested that the
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relationship might represent a ‘thrifty phenotype’—an
acquired rather than inherited defect—which was
expressed as type 2 diabetes when those with the
genotype were exposed to a more affluent nutritional
environment222.
It appears that foetal adaptations take place during times
of undernutrition. Some organs and systems may be
permanently altered or programmed to develop certain
diseases later in life. Examples of this are the outcomes
regarding adults who were in utero during the Dutch
famine. They were about 200 g lighter at birth than those
who were not exposed to the famine. As adults they show
a reduced glucose tolerance and evidence of insulin
resistance228. Birth weight serves as a marker for foetal
nutrition and growth229. There is evidence to suggest that
thin babies are more likely to develop type 2 diabetes214,
as are short fat babies230.
It is important to appreciate that intrauterine growth
retardation may not necessarily be due to deficiencies in
maternal nutrition. A cohort study undertaken in Ports-
mouth on 693 nulliparous white women with singleton
pregnancies showed that placental and infant birth weights
were not associated with the intake of energy or any
macronutrient intakes early or later in pregnancy231. The
researchers suggest that among relatively well-nourished
women in industrialised countries, maternal nutrition may
only have a marginal effect on infant and placental size.
Animal studies have shown that a protein or energy
deficient maternal diet can result in offspring having
abnormal proportions at birth221. Two studies on the long-
term effects of maternal diet in humans have indicated that
the ratio of animal protein to carbohydrate may play a
significant role in birth weight outcome232,233.
Thus, while intrauterine growth retardation would seem
to be well established as a risk factor for the later
development of diabetes, the precise role of maternal diet
is less well established.
Breastfeeding
Early feeding may also play a role in subsequent
development of type 2 diabetes in later life234–236. Bennett
et al.234 found that the prevalence of diabetes was
about 50% lower in Pima Indians who had been
exclusively breastfed for the first 2 months of life.
The mechanism for the protective effect of breastfeeding
remains to be established and further confirmatory
evidence is required.
Other risk factors
Several other risk factors have been related to the
development of diabetes. These include several inflamma-
tory markers (e.g. interleukin-6, C-reactive protein, other
cytokines and acute phase reactants)237–240 and variation
in levels of sex hormones241–244 (e.g. low levels of sex
hormone binding globulin in women, low testosterone
levels in men and women with high androgen levels).
Lifestyle modifications and risk reduction
Three recent studies have examined the potential of
lifestyle intervention programmes in reducing progression
of IGT to diabetes. Two randomised controlled trials have
demonstrated that weight loss achieved by an increase in
physical activity and dietary change including reduction in
total and saturated fat and increased dietary fibre can
reduce the incidence of diabetes175,176. Other studies,
which did not involve individual randomisation, provide
confirmatory evidence245,246.
The aim of the Finnish Diabetes Prevention Study
(FDPS)175 was to assess the efficacy of an intensive diet-
exercise programme on prevention of type 2 diabetes in
522 adults with IGT. Overweight subjects were random-
ised either to an intervention group or to a control group.
The intervention group received individual counselling
with respect to diet, weight loss and physical activity.
There was a significant difference in weight loss between
the two groups after 1 year (4.2 versus 0.8 kg) and after 2
years (3.5 versus 0.8 kg) of intervention. The cumulative
incidence of diabetes was 11% in the intervention group
and 23% in the control group. During the trial the risk of
diabetes was reduced by 58% ( P , 0.001) in the
intervention group.
A similar intervention programme was undertaken in
the United States on a larger sample of more than 3000
overweight adults with IGT176. Participants were repre-
sentative of a variety of national groups resident in the
United States. This study – the US Diabetes Prevention
Program (DPP) – included an additional arm whereby
some participants were randomised to the drug metfor-
min. About 29% of the DPP control group developed
diabetes during the follow-up of 3 years. By contrast 22%
of the metformin arm and 14% of the diet and exercise
group developed diabetes. Participants in the diet and
exercise group achieved a 7% weight loss in the first year
and generally sustained a 5% total loss for the duration of
the study.
In both studies, the estimated risk reduction was about
58%. While lifestyle intervention studies such as the
FDPS154 and the DPP176 have shown that quite modest
changes can reduce the progression from IGT to diabetes
by 50–60%, it has not been clear as to whether it will be
possible to translate these findings to larger cohorts or to
maintain these lifestyle changes in the longer term.
The Da Qing Study245 was undertaken over a longer
intervention period (6 years), than the FDPS and the DPP.
The Da Qing Study differed from the FDPS and the DPP in
that participants with IGT were randomised by interven-
tion rather than as individuals, into a control group or into
one of three interventions: diet only, exercise only, or diet
and exercise, in order to test the effectiveness of diet and
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exercise separately. The cumulative incidence of diabetes
after 6 years was 67.7% in the control group, 43.8% in the
diet group, 41.1% in the exercise group and 46% in the diet
plus exercise group. All the groups differed significantly
from the control group (p , 0.05). Proportional hazards
analyses adjusted for differences in baseline BMI and
fasting glucose, were associated with 31% reduction in risk
of developing diabetes with diet alone; 46% reduction in
risk with exercise alone and 42% reduction in risk with diet
and exercise.
These three studies (among others) provide evidence
that risk of developing type 2 diabetes can be reduced by
changes in lifestyle by adults who are at high risk for the
disease. Although the average amount of weight lost was
relatively small, the difference between the incidence of
diabetes in the intervention groups and the control groups
was substantial. The latter finding emphasises the
importance of even a small reduction of weight loss in
conjunction with increase in physical activity in the
prevention of diabetes. In addition, some intervention
studies have demonstrated benefits in terms of several
cardiovascular risk factors in addition to improved glucose
tolerance175,246,247.
While these trials are of enormous importance, it is
nevertheless equally important to appreciate that even in
the intensive intervention groups an appreciable pro-
portion goes on to develop type 2 diabetes and that the
number of individuals progressing to diabetes increases
with time. It is not clear whether this is due to inability to
sustain the necessary intensive lifestyle interventions or
whether this is due to deteriorating b cell function. It is well
established that the increased insulin secretion evident
prior to the development of hyperglycaemia starts to
reduce even during the phase of IGT and declines
progressively as the disease process continues, regardless
of treatment. Thus, the greatest hope of truly ‘preventing’
type 2 diabetes probably lies not in identifying those with
IGT but rather in implementing lifestyle intervention
programmes in populations at large (especially those at
high risk of type 2) or in individuals at the stage of insulin
resistance.
Recommendations and policy implications
The enormous economic, social and personal cost of type
2 diabetes make a compelling case for prevention.
In recent years, there has been much new evidence
demonstrating the potentially preventable nature of type 2
diabetes, particularly by the implementation of lifestyle
measures such as weight control and exercise. In view of
this and the devastating health impact of the disease it
seems prudent that primary prevention should be a major
priority. Tables 1 and 2 summarise the current evidence
and recommendations made with respect to the develop-
ment of type 2 diabetes.
Since the 1970s there have been numerous health
promotion projects that have attempted to encourage
people to lead a healthier lifestyle. These have been
carried out variously in the community, in doctors’ offices
or at the worksite. While some have achieved success,
more often their impact on the lifestyle of the intended
target audience has been rather limited. It seems likely that
even a modest change in diet and exercise habits can be of
considerable importance when extrapolated to the
population.
In order to achieve maximum benefit from lifestyle
interventions changes in government policies and
legislation will be needed in addition to individual
and community-based programmes248. This would
include mandating more nutrition education in schools,
banning the advertising of unhealthy products and
subsidising healthy foods at the expense of less
appropriate foods.
Despite much research on nutritional factors in the
aetiology of type 2 diabetes, the risk associated with
several individual nutrients is not entirely clear. Thus,
evidence-based advice to governments and public
health authorities emphasises the role of weight
reduction in the overweight and obese and an increase
in physical activity. This approach can also be expected
to have a positive effect for prevention of other major
non-communicable diseases such as cardiovascular
disease and hypertension.
Many developing countries now report the onset of type
2 diabetes at an increasingly young age. This trend
towards younger age of onset implies a huge additional
burden to the individuals and society and necessitates a
lifetime approach to prevention.
In making recommendations to governments regarding
the prevention of type 2 diabetes, priority should be given
to the following:
1. Promotion and evaluation of ‘healthy’ lifestyle
programmes, which focus on the following aspects:
. Prevention and early treatment of overweight and
obesity, particularly in high risk groups;
. Consumption of a nutrient-dense diet, which is
low in fat, particularly saturated fat, and free sugars
and high in NSPs.
. An active lifestyle, which includes regular physical
activity of at least 1 hr/day, and vigorous activity,
which is required to reduce the risk of developing
type 2 diabetes.
. Moderate alcohol intake and cessation of cigarette
smoking.
. Demonstration projects in developing and devel-
oped countries since it is recognised that there is a
paucity of data on the efficacy of community-
based lifestyle programmes.
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2. Early identification of subjects at risk of developing type
2 diabetes
. Identifying subjects at high risk of hypertension,
diabetes and heart disease;
. Screening for gestational diabetes;
. Optimal maternal nutrition and weight
maintenance.
3. Healthy lifestyle programmes/interventions should
focus on a life course perspective and not on a specific
age group or developmental stage.
4. Legislative action will be necessary to promote a
healthier lifestyle for all populations. All governments
and their employees in the social, health, nutritional,
economic and welfare arenas should move forward on
an integrated approach to the prevention of the disease
and not only in treating the symptoms. There is
compelling evidence for the benefits likely to accrue
from policies and programmes aimed at reducing rates
of overweight andobesity, at increasingphysical activity
and at reducing intakeof saturated fatty acids. Individual
countries, based on their national and individual food
preferences, should develop dietary recommendations
that are more specific in this regard.
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Intrauterine growth retardation (IUGR)
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‡ As a global public health recommendation, infants should be exclusively breastfed for the first six months of life to achieve optimal growth, development
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Vigorous activity is required to reduce
the risk of developing type 2 diabetes
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